Survivin rs9904341 polymorphism significantly increased the risk of cancer: evidence from an updated meta-analysis of case–control studies

  • Abdolkarim Moazeni-Roodi
  • Saeid Ghavami
  • Mohammad HashemiEmail author
Review Article



Survivin, a member of inhibitor of apoptosis protein family, is involved in the regulation of cell cycle and apoptosis. Several studies inspected the association between survivin polymorphisms and the risk of various cancers, but the findings remain controversial. We conducted a meta-analysis intending to certify the association between survivin polymorphisms and cancer risk.


All analyses were achieved using RevMan 5.3 software and STATA 14.1 software. Eligible studies were collected by comprehensive literature searching Web of Science, PubMed, Scopus, and Google scholar databases. Pooled estimates of odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the overall impact of survivin polymorphisms on cancer risk.


The overall analysis indicates that survivin rs9904341 polymorphism significantly increased the risk of cancer in homozygous codominant (OR 1.41, 95% CI 1.19–1.68, p = 0.0001, CC vs GG), dominant (OR 1.22, 95% CI 1.07–1.40, p = 0.003, CG+CC vs GG), recessive (OR 1.34, 95% CI 1.18–1.52, p < 0.0001, CC vs CG+GG), and allele (OR 1.20, 95% CI 1.09–1.31, p = 0.0001, C vs G) inheritance models tested. Stratified based on ethnicity revealed that rs9904341 variant significantly increased the risk of cancer in the Asian population. The findings did not support an association between rs1042489, rs2071214, rs8073069, and rs17878467 polymorphisms and risk of cancer.


The current study suggests that the survivin rs9904341 polymorphism may be associated with the risk of cancer either overall or in the Asian population. However, further larger and well-designed studies are warranted to evaluate this association in detail.


Survivin Polymorphism Cancer Meta-analysis 


Compliance with ethical standards

Conflict of interest

The authors have declared that no competing interests exist.


  1. 1.
    Global Burden of Disease Cancer C, Fitzmaurice C, Dicker D et al (2015) The global burden of cancer 2013. JAMA Oncol 1(4):505–527. Google Scholar
  2. 2.
    Lichtenstein P, Holm NV, Verkasalo PK et al (2000) Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343(2):78–85. Google Scholar
  3. 3.
    Shastry BS (2009) SNPs: impact on gene function and phenotype. Methods Mol Biol 578:3–22. Google Scholar
  4. 4.
    Hashemi M, Tabasi F, Ansari H (2018) 4-bp insertion/deletion polymorphism within the promoter of EGLN2 gene is associated with susceptibility to cancer in Asian population: evidence from a meta-analysis. Meta Gene 17:141–146. Google Scholar
  5. 5.
    Altieri DC (2001) The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 7(12):542–547Google Scholar
  6. 6.
    Johnson ME, Howerth EW (2004) Survivin: a bifunctional inhibitor of apoptosis protein. Vet Pathol 41(6):599–607. Google Scholar
  7. 7.
    Krepela E, Dankova P, Moravcikova E et al (2009) Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma. Int J Oncol 35(6):1449–1462Google Scholar
  8. 8.
    Moosavi MA, Rahmati M, Ashtari N et al (2017) Apoptosis, autophagy, and unfolded protein response and cerebellar development. In: Marzban H (ed) Development of the cerebellum from molecular aspects to diseases. Springer, Cham, pp 153–178. Google Scholar
  9. 9.
    Fangusaro JR, Caldas H, Jiang Y et al (2006) Survivin: an inhibitor of apoptosis in pediatric cancer. Pediatr Blood Cancer 47(1):4–13. Google Scholar
  10. 10.
    Lopez J, Meier P (2010) To fight or die—inhibitor of apoptosis proteins at the crossroad of innate immunity and death. Curr Opin Cell Biol 22(6):872–881. Google Scholar
  11. 11.
    Melet A, Song K, Bucur O et al (2008) Apoptotic pathways in tumor progression and therapy. Adv Exp Med Biol 615:47–79. Google Scholar
  12. 12.
    Cheung CH, Huang CC, Tsai FY et al (2013) Survivin—biology and potential as a therapeutic target in oncology. Onco Targets Ther 6:1453–1462. Google Scholar
  13. 13.
    Rosato A, Menin C, Boldrin D et al (2013) Survivin expression impacts prognostically on NSCLC but not SCLC. Lung Cancer 79(2):180–186. Google Scholar
  14. 14.
    Wu SF, Zhang JW, Qian WY et al (2012) Altered expression of survivin, Fas and FasL contributed to cervical cancer development and metastasis. Eur Rev Med Pharmacol Sci 16(15):2044–2050Google Scholar
  15. 15.
    Zhang LQ, Wang J, Jiang F et al (2012) Prognostic value of survivin in patients with non-small cell lung carcinoma: a systematic review with meta-analysis. PLoS One 7(3):e34100. Google Scholar
  16. 16.
    Aynaci E, Coskunpinar E, Eren A et al (2013) Association between survivin gene promoter − 31G/C and − 644C/T polymorphisms and non-small cell lung cancer. Genet Mol Res 12(3):3975–3982. Google Scholar
  17. 17.
    Guo G, Zhang Q, Yu Z et al (2015) Correlation between survivin genetic polymorphisms and lung cancer susceptibility. Int J Clin Exp Pathol 8(6):7426–7430Google Scholar
  18. 18.
    Jang JS, Kim KM, Kang KH et al (2008) Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer 60(1):31–39. Google Scholar
  19. 19.
    Javid J, Mir R, Julka PK et al (2015) Role of survivin re-expression in the development and progression of non-small cell lung cancer. Tumour Biol 36(7):5543–5550. Google Scholar
  20. 20.
    Zhang X-e, Chen Y, Li H-r et al (2012) The relationship of rs9904341 polymorphism with lung cancer susceptibility and sensitivity of platinum-based chemotherapy in patients with lung cancer. China Cancer 21:533–538Google Scholar
  21. 21.
    Aminimoghaddam S, Shahrabi-Farahani M, Mohajeri-Tehrani M et al (2015) Epistatic interaction between adiponectin and survivin gene polymorphisms in endometrial carcinoma. Pathol Res Pract 211(4):293–297. Google Scholar
  22. 22.
    Antonacopoulou AG, Floratou K, Bravou V et al (2010) The survivin—31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival. Anal Cell Pathol (Amst) 33(5):177–189. Google Scholar
  23. 23.
    Bagheri Z, Mohamadynejad P, Moghanibashi M (2017) Increased risk of gastric cancer in the CC genotype-31C/G polymorphism in Survivin gene promoter. J Gorgan Univ Med Sci 19:3Google Scholar
  24. 24.
    Bayram S, Akkiz H, Bekar A et al (2011) The association between the survivin − 31G/C promoter polymorphism and hepatocellular carcinoma risk in a Turkish population. Cancer Epidemiol 35(6):555–559. Google Scholar
  25. 25.
    Bogdanovic L, Lazic M, Bogdanovic J et al (2017) Polymorphisms of survivin − 31 G/C gene are associated with risk of urothelial carcinoma in Serbian population. J Buon 22(1):270–277Google Scholar
  26. 26.
    Borbely AA, Murvai M, Szarka K et al (2007) Survivin promoter polymorphism and cervical carcinogenesis. J Clin Pathol 60(3):303–306. Google Scholar
  27. 27.
    Borges Bdo N, Burbano RR, Harada ML (2011) Survivin – 31C/G polymorphism and gastric cancer risk in a Brazilian population. Clin Exp Med 11(3):189–193. Google Scholar
  28. 28.
    Chen J, Cui X, Zhou H et al (2013) Functional promoter – 31G/C variant of Survivin gene predict prostate cancer susceptibility among Chinese: a case control study. BMC Cancer 13:356. Google Scholar
  29. 29.
    Cheng ZJ, Hu LH, Huang SJ (2008) Correlation of − 31G/C polymorphisms of survivin promoter to tumorigenesis of gastric carcinoma. Ai Zheng 27(3):258–263Google Scholar
  30. 30.
    El-Said H, El-Hakim TA, Obada M et al (2016) Study of survivin gene expression in hepatocellular carcinoma patients. Menoufia Med J 29(4):912Google Scholar
  31. 31.
    Gazouli M, Tzanakis N, Rallis G et al (2009) Survivin – 31G/C promoter polymorphism and sporadic colorectal cancer. Int J Colorectal Dis 24(2):145–150. Google Scholar
  32. 32.
    Hsieh YS, Tsai CM, Yeh CB et al (2012) Survivin T9809C, an SNP located in 3′-UTR, displays a correlation with the risk and clinicopathological development of hepatocellular carcinoma. Ann Surg Oncol 19(Suppl 3):S625–S633. Google Scholar
  33. 33.
    Huang Z-M, Chiang Y-T, Tung M-C et al (2013) Survivin promoter rs9904341 polymorphism is associated with tumor stage and grade in patients with bladder cancer. Adv Biosci Biotechnol 4(01):1Google Scholar
  34. 34.
    Jaiswal PK, Goel A, Mandhani A et al (2012) Functional polymorphisms in promoter survivin gene and its association with susceptibility to bladder cancer in North Indian cohort. Mol Biol Rep 39(5):5615–5621. Google Scholar
  35. 35.
    Karimian M, Aftabi Y, Mazoochi T et al (2018) Survivin polymorphisms and susceptibility to prostate cancer: a genetic association study and an in silico analysis. EXCLI J 17:479–491. Google Scholar
  36. 36.
    Kawata N, Tsuchiya N, Horikawa Y et al (2011) Two survivin polymorphisms are cooperatively associated with bladder cancer susceptibility. Int J Cancer 129(8):1872–1880. Google Scholar
  37. 37.
    Kostic M, Nikolic N, Ilic B et al (2013) Analysis of polymorphism in the survivin gene promoter as a potential risk factor for head and neck cancers development. Srp Arh Celok Lek 141(5–6):304–307Google Scholar
  38. 38.
    Li WX, Li YK, Lin HT (2018) Correlation between survivin polymorphism and acute leukemia of children. Exp Ther Med 15(3):2941–2945. Google Scholar
  39. 39.
    Liarmakopoulos E, Theodoropoulos G, Vaiopoulou A et al (2013) Effects of stromal cell-derived factor-1 and survivin gene polymorphisms on gastric cancer risk. Mol Med Rep 7(3):887–892. Google Scholar
  40. 40.
    Li Y, Wang J, Jiang F et al (2012) Association of polymorphisms in survivin gene with the risk of hepatocellular carcinoma in Chinese han population: a case control study. BMC Med Genet 13:1. Google Scholar
  41. 41.
    Lin YC, Hour TC, Tsai YC et al (2017) Preliminary evidence of polymorphisms of cell cycle regulatory genes and their roles in urinary tract urothelial cancer susceptibility and prognosis in a Taiwan population. Urol Oncol 35(9):543 e547–543 e516. Google Scholar
  42. 42.
    Ma F, Zhang H, Zhai Y et al (2011) Functional polymorphism – 31C/G in the promoter of BIRC5 gene and risk of nasopharyngeal carcinoma among chinese. PLoS One 6(2):e16748. Google Scholar
  43. 43.
    Marques I, Teixeira AL, Ferreira M et al (2013) Influence of survivin (BIRC5) and caspase-9 (CASP9) functional polymorphisms in renal cell carcinoma development: a study in a southern European population. Mol Biol Rep 40(8):4819–4826. Google Scholar
  44. 44.
    Qin C, Cao Q, Li P et al (2012) Functional promoter – 31G> C variant in survivin gene is associated with risk and progression of renal cell cancer in a Chinese population. PLoS One 7(1):e28829. Google Scholar
  45. 45.
    Qin L, Yu T (2015) Association between rs9904341 G < C gene polymorphism and susceptibility to pancreatic cancer in a Chinese population. Genet Mol Res 14(2):5197–5202. Google Scholar
  46. 46.
    Radojevic-Skodric S, Basta-Jovanovic G, Brasanac D et al (2012) Survivin gene promoter – 31 G/C polymorphism is associated with Wilms tumor susceptibility in Serbian children. J Pediatr Hematol Oncol 34(8):e310–e314. Google Scholar
  47. 47.
    Rasool I, Afroze D, Wani KA et al (2018) Role of the functional polymorphism of survivin gene (− 31G/C) and risk of breast cancer in a North Indian population. Clin Breast Cancer 18(4):e671–e676. Google Scholar
  48. 48.
    Theodoropoulos GE, Michalopoulos NV, Panoussopoulos SG et al (2010) Effects of caspase-9 and survivin gene polymorphisms in pancreatic cancer risk and tumor characteristics. Pancreas 39(7):976–980. Google Scholar
  49. 49.
    Upadhyay R, Khurana R, Kumar S et al (2011) Role of survivin gene promoter polymorphism (− 31G> C) in susceptibility and survival of esophageal cancer in northern India. Ann Surg Oncol 18(3):880–887. Google Scholar
  50. 50.
    Yang L, Zhu H, Zhou B et al (2009) The association between the survivin C-31G polymorphism and gastric cancer risk in a Chinese population. Dig Dis Sci 54(5):1021–1028. Google Scholar
  51. 51.
    Weng CJ, Hsieh YH, Chen MK et al (2012) Survivin SNP-carcinogen interactions in oral cancer. J Dent Res 91(4):358–363. Google Scholar
  52. 52.
    Yamak N, Yaykasli KO, Yilmaz U et al (2014) Association between survivin gene polymorphisms and the susceptibility to colon cancer development in the Turkish population. Asian Pac J Cancer Prev 15(20):8963–8967Google Scholar
  53. 53.
    Yang X, Xiong G, Chen X et al (2009) Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 135(10):1341–1349. Google Scholar
  54. 54.
    Yazdani N, Sayahpour FA, Haghpanah V et al (2012) Survivin gene polymorphism association with papillary thyroid carcinoma. Pathol Res Pract 208(2):100–103. Google Scholar
  55. 55.
    Zahedi P, Aminimoghaddam S, Sayahpour FA et al (2012) Association of survivin gene polymorphism with endometrial cancer. Int J Gynecol Cancer 22(1):35–37. Google Scholar
  56. 56.
    Ghavami S, Hashemi M, Ande SR et al (2009) Apoptosis and cancer: mutations within caspase genes. J Med Genet 46(8):497–510. Google Scholar
  57. 57.
    Li D, Hu C, Li H (2018) Survivin as a novel target protein for reducing the proliferation of cancer cells. Biomed Rep 8(5):399–406. Google Scholar
  58. 58.
    Martinez-Garcia D, Manero-Ruperez N, Quesada R et al (2018) Therapeutic strategies involving survivin inhibition in cancer. Med Res Rev. Google Scholar
  59. 59.
    Xu Y, Fang F, Ludewig G et al (2004) A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol 23(7):419–429. Google Scholar
  60. 60.
    Xu Y, Fang F, Ludewig G et al (2004) A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol 23(9):527–537. Google Scholar
  61. 61.
    Zhu Y, Li Y, Zhu S et al (2013) Association of survivin polymorphisms with tumor susceptibility: a meta-analysis. PLoS One 8(9):e74778. Google Scholar
  62. 62.
    Srivastava K, Srivastava A, Mittal B (2012) Survivin promoter – 31G/C (rs9904341) polymorphism and cancer susceptibility: a meta-analysis. Mol Biol Rep 39(2):1509–1516. Google Scholar
  63. 63.
    Qin Q, Zhang C, Zhu H et al (2014) Association between survivin – 31G> C polymorphism and cancer risk: meta-analysis of 29 studies. J Cancer Res Clin Oncol 140(2):179–188. Google Scholar
  64. 64.
    Zhou X, Lin C (2015) Survivin and angiotensin-converting enzyme polymorphisms with risk of colorectal cancer: a systematic review and meta-analysis. World J Surg Oncol 13:27. Google Scholar
  65. 65.
    Liu Y, Li L, Qi H et al (2013) Survivin – 31G> C polymorphism and gastrointestinal tract cancer risk: a meta-analysis. PLoS One 8(2):e54081. Google Scholar
  66. 66.
    Zhang S, Zhang C, Song Y et al (2018) Prognostic role of survivin in patients with glioma. Medicine (Baltimore) 97(17):e0571. Google Scholar
  67. 67.
    Pu Z, Wang Q, Xie H et al (2017) Clinicalpathological and prognostic significance of survivin expression in renal cell carcinoma: a meta-analysis. Oncotarget 8(12):19825–19833. Google Scholar
  68. 68.
    Xia H, Chen S, Huang H et al (2015) Survivin over-expression is correlated with a poor prognosis in esophageal cancer patients. Clin Chim Acta 446:82–85. Google Scholar
  69. 69.
    Li Y, Ma X, Wu X et al (2014) Prognostic significance of survivin in breast cancer: meta-analysis. Breast J 20(5):514–524. Google Scholar
  70. 70.
    Krieg A, Mahotka C, Krieg T et al (2002) Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br J Cancer 86(5):737–743. Google Scholar
  71. 71.
    Dizdar L, Tomczak M, Werner TA et al (2017) Survivin and XIAP expression in distinct tumor compartments of surgically resected gastric cancer: XIAP as a prognostic marker in diffuse and mixed type adenocarcinomas. Oncol Lett 14(6):6847–6856. Google Scholar
  72. 72.
    He X, Yang K, Wang H et al (2018) Expression and clinical significance of survivin in ovarian cancer: a meta-analysis. PLoS One 13(5):e0194463. Google Scholar
  73. 73.
    Geng J, Lei YR, Pei SG (2017) Correlation between Survivin expression and laryngeal carcinoma: a meta-analysis. J Huazhong Univ Sci Technol Med Sci 37(6):965–973. Google Scholar
  74. 74.
    Li W, Lee MR, Choi E et al (2017) Clinicopathologic significance of survivin expression in relation to CD133 expression in surgically resected stage II or III colorectal cancer. J Pathol Transl Med 51(1):17–23. Google Scholar
  75. 75.
    Wang H, Jin S, Lu H et al (2017) Expression of survivin, MUC2 and MUC5 in colorectal cancer and their association with clinicopathological characteristics. Oncol Lett 14(1):1011–1016. Google Scholar
  76. 76.
    Krieg A, Baseras B, Tomczak M et al (2013) Role of survivin as prognostic and clinicopathological marker in gastric cancer: a meta-analysis. Mol Biol Rep 40(9):5501–5511. Google Scholar

Copyright information

© Japan Society of Clinical Oncology 2019

Authors and Affiliations

  1. 1.Department of Clinical BiochemistryIranshahr University of Medical SciencesIranshahrIran
  2. 2.Department of Human Anatomy and Cell Science, Rady Faculty of Health SciencesMax Rady College of Medicine, University of ManitobaWinnipegCanada
  3. 3.Research Institute in Oncology and Hematology, CancerCare ManitobaUniversity of ManitobaWinnipegCanada
  4. 4.Genetics of Non-communicable Disease Research CenterZahedan University of Medical SciencesZahedanIran
  5. 5.Department of Clinical Biochemistry, School of MedicineZahedan University of Medical SciencesZahedanIran

Personalised recommendations